Pelthos Therapeutics Inc.
AMEX:PTHSBiotechnology
-$0.37 today
- Market cap
- $63.32M
- Beta
- 3.13
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$15.58
Volume 0.01M
Average 0.04M
PTHS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Pelthos Therapeutics Inc.AMEX: PTHS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $186K fell 4.3% year over year, behind the +34.5% change in trailing-twelve-month research & development. Sequentially, it fell 50.3% from the prior quarter. Over 3 fiscal years it compounded at +46.4% a year.
Context
- Research & development amounted to 7.3% of revenue in FY2025.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.3% toward the trailing-twelve-month pace of +34.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.23M USD
- Year-over-year change
- +4.1%
- 4-year CAGR
- +55.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.23M | +4.1% |
| FY2024 | 2024-12-31 | 1.18M | -54.3% |
| FY2023 | 2023-12-31 | 2.58M | +558.5% |
| FY2022 | 2022-12-31 | 391.73K | +87.4% |
| FY2021 | 2021-12-31 | 209.05K | — |
Research & Development vs competitors
How PTHS compares with its peers on the latest reported figures
- PTHS's LTM Mar 2026 research & development of $1.22M is the 3rd highest of the 4 companies compared; the peer median is $9.2M.
- Its year-over-year change of +34.5% is the highest of 4, against a peer median of -13.4%.
- Research & development amounts to 4.4% of revenue for PTHS.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.74M | -1.3% | +2.8% | — | |
| LTM Dec 2025 | $9.2M | -13.4% | -21.9% | — | |
| LTM Mar 2026 | $1.22M | +34.5% | +46.4% | 4.4% | |
| LTM Mar 2026 | $496.84K | -28.9% | -42.6% | — | |
| Peer median (excluding PTHS) | $9.2M | -13.4% | -21.9% | — | |
Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 16.8M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 9.37M |
| Gross Profit | 0 | 0 | 0 | 0 | 7.43M |
| Gross Margin | — | — | — | — | 44.2% |
| Research & Development | 209.05K | 391.73K | 2.58M | 1.18M | 1.23M |
| Selling, General & Admin | 629.95K | 1.93M | 4.28M | 6.39M | 37.08M |
| Operating Expenses | 839K | 2.32M | 6.86M | 7.57M | 39.86M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 2.29M |
| EBITDA | (595.13K) | (2.32M) | (6.86M) | (7.17M) | (45.41M) |
| EBITDA Margin | — | — | — | — | -270.4% |
| Operating Income | (839K) | (2.32M) | (6.86M) | (7.57M) | (32.43M) |
| Operating Margin | — | — | — | — | -193.1% |
| Interest Income | 0 | 0 | 0 | 0 | 5K |
| Interest Expense | 253 | 140.43K | 518.51K | 786.39K | 3.01M |
| Other Income / Expenses | 243.61K | (140.43K) | (518.51K) | (383.89K) | (18.28M) |
| Income Before Tax | (595.39K) | (2.46M) | (7.38M) | (7.96M) | (50.71M) |
| Pre-Tax Margin | — | — | — | — | -301.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | (7.39M) |
| Net Income | (595.39K) | (2.46M) | (7.38M) | (7.96M) | (43.32M) |
| Net Margin | — | — | — | — | -257.9% |
| EPS (Basic) | (1.00) | (4.26) | (12.80) | (13.54) | (23.04) |
| EPS (Diluted) | (1.00) | (4.26) | (12.80) | (13.54) | (23.04) |
| Weighted Avg Shares | 576.75K | 576.75K | 576.75K | 587.62K | 1.88M |
| Weighted Avg Shares (Diluted) | 576.75K | 576.75K | 576.75K | 587.62K | 1.88M |
Pelthos Therapeutics Inc.
AMEX:PTHS
Intrinsic Alpha fair value
Locked
Current Price
$16.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.